Abdulilah Ece

Prof. Dr. Abdulilah Ece

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SASercan Askin
Sercan Askin
HTHakan Tahtaci
Hakan Tahtaci
CTCüneyt Türkeş
Cüneyt Türkeş
YDYeliz Demir
Yeliz Demir
AEAbdulilah Ece
Abdulilah Ece
ŞBŞükrü Beydemir
Şükrü Beydemir

24 March 2023 in BMC Chemistry
Verified
Journal Article
Open access
PDF file
AEAbdulilah Ece
Abdulilah Ece
Computer-Aided Drug Design tools are now an indispensable part of drug discovery that have made key contributions to the development of drugs. In this editorial, I briefly provide an overview of CADD emphasizing its potential and invite authors from academia and the pharmaceutical and biotechnology sector to present their research in this collection.

1 January 2022 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Yahya NuralYahya Nural
Yahya Nural
SOSadin Ozdemir
Sadin Ozdemir
MYMustafa Serkan Yalcin
Mustafa Serkan Yalcin
BDBunyamin Demir
Bunyamin Demir
HAHasan Atabey
Hasan Atabey
AEAbdulilah Ece
Abdulilah Ece

24 July 2025 in Bioorganic Chemistry
Verified
Journal Article
Closed access
BZBlinera Zognjani
Blinera Zognjani
ARArleta Rifati-Nixha
Arleta Rifati-Nixha
HDHatice Esra Duran
Hatice Esra Duran
MAMustafa Arslan
Mustafa Arslan
GYGizem Yıldıztekin
Gizem Yıldıztekin
CTCüneyt Türkeş
Cüneyt Türkeş

4 August 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
ÖGÖzcan Güleç
Özcan Güleç
CTCüneyt Türkeş
Cüneyt Türkeş
MAMustafa Arslan
Mustafa Arslan
YDYeliz Demir
Yeliz Demir
BDBusra Dincer
Busra Dincer
ŞBŞükrü Beydemir
Şükrü Beydemir
In this study, a library of twelve beta-lactam-substituted benzenesulfonamides (5a-l) was synthesized using the tail-approach method. The compounds were characterized using IR, 1H NMR, 13C NMR and elemental analysis techniques. These newly synthesized compounds were tested for their ability to inhibit the activity of two carbonic anhydrases (hCA) isoforms, I and II, and acetylcholinesterase (AChE) in vitro. The results showed that the synthesized compounds were potent inhibitors of hCA I, with KIs in the low nanomolar range (66.60-278.40 nM) than the reference drug acetazolamide (AAZ), which had a KI of 439.17 nM. The hCA II was potently inhibited by compounds 5a, 5d-g and 5l, with KIs of 69.56, 39.64, 79.63, 74.76, 78.93 and 74.94 nM, respectively (AAZ, KI of 98.28 nM). Notably, compound 5a selectively inhibited hCA II with a selectivity of > 4-fold over hCA I. In terms of inhibition of AChE, the synthesized compounds had KIs ranging from 30.95 to 154.50 nM, compared to the reference drug tacrine, which had a KI of 159.61 nM. Compounds 5f, 5h and 5l were also evaluated for their ability to inhibit the MCF-7 cancer cell line proliferation and were found to have promising anticancer activity, more potent than 5-fluorouracil and cisplatin. Molecular docking studies suggested that the sulfonamide moiety of these compounds fits snugly into the active sites of hCAs and interacts with the Zn2+ ion. Furthermore, molecular dynamics simulations were performed for 200 ns to assess the stability and dynamics of each enzyme-ligand complex. The acceptability of the compounds based on Lipinski's and Jorgensen's rules was also estimated from the ADME/T results. These results indicate that the synthesized molecules have the potential to be developed into effective and safe inhibitors of hCAs and AChE and could be lead agents.Communicated by Ramaswamy H. Sarma.